Related coverage linked through entity extraction aliases.
Aug 13, 2026
A 19-month-old girl with influenza A (H1N1)-associated acute necrotizing encephalitis made a complete neurological recovery despite a severity score of 6. Multimodal immunomodulatory therapy including IVIG, corticosteroids, anakinra, and plasma exchange led to rapid decline in blood cytokine levels. The case underscores early recognition and targeted treatment in young children.
Jul 17, 2026
New imaging reveals that most flu infections fail due to transcription errors, while host-targeted antivirals aim to bypass resistance by interfering with cellular machinery. The findings from Cell Systems point to new ways to predict viral threats and develop broad-spectrum drugs.
May 31, 2026
Two new studies reveal long COVID's lasting biological and mental health effects. A mouse study found coronavirus triggers prolonged lung and brain damage unlike influenza, while a population study linked long COVID to significantly higher depression and anxiety risks up to three years post-infection.
Apr 10, 2026
The CDC reported six new influenza-associated pediatric deaths in Week 6 of 2026, bringing the 2025-2026 U.S. season total to 71. About 90% of deaths with known vaccination status were in children not fully vaccinated.
Feb 19, 2026
Moderna announced the FDA will consider approving its mRNA-based flu vaccine for older adults after resolving a dispute over clinical trial design. The vaccine showed 34.5% higher efficacy than standard flu shots in trials.
Feb 20, 2026
Vir Biotechnology is set to report Q4 2025 earnings on Feb 23, 2026, with analysts expecting revenue of $19.91-$23.18 million and a loss of $0.41-$0.50 per share, marking a 61% year-over-year revenue increase.
